T-Knife Therapeutics is developing novel T cell engineered therapeutics to fight cancer. T cell receptor (TCR) engineered T cells are a promising new therapeutic modality. T-Knife is discovering high affinity and high specificity human TCRs that can be used to supercharge T cells. Through the use of natural, fully human TCRs and tailored armoring, T-Knife’s product candidates are designed to optimize the immune signaling cascade to drive potent T cell responses against tumors. T-Knife’s pipeline includes TCR therapies that target tumor antigens in multiple, difficult to treat solid tumor indications.

T-Knife Therapeutics

Working Student - Quality

Working Student

T-knife will be presenting our supercharged TCR-T technologies and discussing the overall oncology landscape at the BIO International Convention. If you will be in San Diego, contact us to meet: https://lnkd.in/eSMYVsWE

Our CTOO Simone Steiner will be sharing her technical development and manufacturing expertise in three speaking engagements at the Advanced Therapies Europe conference in Lisbon, Portugal this week. If you would like to meet with her, contact us: https://lnkd.in/eSMYVsWE #ATE24 #AdvancedTherapies #Biotech

We recognize our LGBTQI+ family, friends, colleagues and community members this month and every month as we celebrate the power of expression and diversity. #PrideMonth

T-knife Therapeutics Announces the Appointment of Megan Baierlein as Chief Operating Officer

T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting

T-knife Therapeutics bags $110M to sharpen solid tumor cell therapy push into the clinic - Fierce Biotech

T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer 

T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting

Donna Osburn - Vacaville Reporter

Kite’s head of research leaves for Flagship startup Sonata - Endpoints News

At the TCR Summit, our CSO Peggy Sotiropoulou will review how we are developing supercharged TCR-Ts that incorporate multiple best-in-class technologies, including armoring techniques that aim to fortify TCR-T cells. Conference info: https://lnkd.in/gF2zkg8 

Our CEO Tom Soloway and CFO/CBO Camille Landis will be in Miami starting tomorrow to participate in the Evercore HealthCONx Conference. If you are in town and would like to connect, contact us: https://lnkd.in/eSMYVsWE

T-knife Therapeutics bags $110M to sharpen solid tumor ...

Chutes & Ladders—Gene editing biotech Metagenomi adds CSO, CFO - Fierce Biotech

T-knife Therapeutics Appoints Peggy Sotiropoulou, Ph.D. as Chief Scientific Officer

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

Thank you Brad Loncar for speaking with our team about the innovative TCR-T therapy that T-knife is advancing towards the clinic and the exciting data being generated in the field of T cell therapies that are benefiting patients with cancer.

Our CTO and co-founder, Elisa Kieback, will be presenting at the #BIOEuropeSpring Conference on March 19th in Barcelona, Spain. If you’re attending, we hope to see you there! https://lnkd.in/eRdjEqv 

T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer - GlobeNewswire

The CAR-TCR Summit Series is a premier conference bringing together industry leaders to review scientific and technical progress and data on T-cell based therapies. At next week’s conference, our CTO Elisa Kieback and CSO Peggy Sotiropoulou will share insights based on our leading platform for T cell receptor engineered T cell therapies (TCR-Ts). #CARTCR 

T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial 

On #WorldCancerResearchDay, we want to recognize the scientists who have made important discoveries in our understanding of cancer, resulting in innovative therapeutics that are extending patients’ lives. At T-knife, we are building upon this growing body of knowledge to develop Supercharged T cell therapies to treat solid tumors.

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies - GlobeNewswire

Chutes & Ladders—Former Roche pharma chief tapped to be new Bayer CEO - Fierce Biotech

T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel

T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors

T-knife Therapeutics Announces the Appointment of Donald Wuchterl as Senior Vice President and Chief Manufacturing Officer

T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting

T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Congratulations to our friends at Adaptimmune on this incredible achievement! Their first-in-class approval of Tecelra provides an important new therapy for patients living with synovial sarcoma, and it is a landmark milestone for the field of solid tumor focused cell therapies.

T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T

People - Nature.com

T-Knife Therapeutics

Business:

Drug notes:

About: